Alnylam Pharmaceuticals, Inc. ( ALNY) - Stock Earnings
ALNY Upcoming earnings
Estimated EPS and revenue columns are available to paid members.
| Date | EPS (actual / est.) | Revenue low (est.) | Revenue (actual / est.) | Revenue high (est.) |
|---|---|---|---|---|
| July 30, 2026, midnight | — / — | — | — / — | — |
ALNY Quarterly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2025Q3 | 251.1 million USD | 1.2 billion USD |
| 2025Q4 | 186.4 million USD | 1.1 billion USD |
| 2026Q1 | 206.0 million USD | 1.2 billion USD |
| 2026Q3 Est. | — | — |
| 2026Q4 Est. | — | — |
ALNY Yearly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -440.2 million USD | 1.8 billion USD |
| 2024 | -278.2 million USD | 2.2 billion USD |
| 2025 | 313.7 million USD | 3.7 billion USD |
| 2026 Est. | — | — |
ALNY
Price: $271.77
Earnings Per Share: 3.97 USD
P/E Ratio: 76.32
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 712302
Ebitda: -143.6 millionMarket Capitalization: 41.8 billion